Back/Quest Diagnostics Launches AI Companion to Enhance Patient Engagement with Lab Results
healthcare·March 4, 2026·dgx

Quest Diagnostics Launches AI Companion to Enhance Patient Engagement with Lab Results

ED
Editorial
Cashu Markets·2 min read
TL;DR
  • Quest Diagnostics launches Quest AI Companion to enhance patient engagement with lab results via the MyQuest app.
  • The AI tool analyzes five years of lab data, providing personalized insights while ensuring HIPAA-compliant privacy.
  • Quest AI Companion promotes informed patient-provider discussions by simplifying complex medical results and terminology.

Empowering Patient Engagement: Quest Diagnostics Launches AI Companion

Quest Diagnostics, a prominent figure in diagnostic information services, introduces its latest innovation, Quest AI Companion, designed to revolutionize how patients interact with their lab results. This AI-powered chat feature, now accessible via the MyQuest app and portal for all adult users, aims to enhance patient understanding of their health data while preserving the integrity of personal information. Committed to maintaining privacy in a growing digital landscape, Quest AI Companion operates within a secure, HIPAA-compliant framework, addressing a significant concern for individuals wary of sharing sensitive health information on public platforms.

The interactive tool leverages artificial intelligence to analyze up to five years of a patient’s laboratory data, providing personalized insights and helping users recognize potential health risks or emerging trends. By delivering tailored explanations of test results, the AI Companion empowers patients to engage more meaningfully with their health information. Nicole Antonson, vice president of digital solutions and interoperability at Quest, emphasizes that this initiative promotes informed discussions between patients and their healthcare providers. Users can expect definitions of tests and medical terminology, clarification of lab values, and assistance in crafting relevant questions for their clinicians, ultimately fostering a more collaborative approach to healthcare.

Despite the increasing integration of AI technologies in healthcare, a recent survey conducted by Quest reveals a significant apprehension among individuals regarding the use of public AI tools due to privacy issues. As noted by Yuri Fesko, M.D., senior vice president at Quest Diagnostics, many patients desire deeper insights into their lab data but hesitate to utilize services that may expose their health information. Quest AI Companion emerges as a solution, allowing patients to benefit from advanced analytics without compromising the confidentiality of their health records. This launch marks a pivotal moment for Quest Diagnostics, reflecting their commitment to enhancing patient engagement and facilitating healthier outcomes through innovative technology.

Additionally, with a focus on simplifying health information, Quest AI Companion seeks to address a common demand from patients for clarity in understanding complex medical results. By making this information more accessible, Quest positions itself as a leader not just in diagnostics but also in patient empowerment through technological advancements. Overall, Quest Diagnostics’ latest offering underscores the growing trend of blending artificial intelligence with healthcare, aiming to support patients in navigating their health journeys more effectively.

Cashu Markets
Cashu
Markets

By Cashu Markets. Providing market news, analysis, and research for investors worldwide.

© 2026 Cashu Technologies Pty Ltd. All rights reserved. Cashu Markets is a trademark of Cashu Technologies Pty Ltd.

The content published on Cashu Markets is for informational purposes only and should not be construed as investment advice, a recommendation, or an offer to buy or sell any securities. All opinions expressed are those of the authors and do not reflect the official position of Cashu Technologies Pty Ltd or its affiliates. Past performance is not indicative of future results. Investing involves risk, including the possible loss of principal. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Cashu Markets and its contributors may hold positions in securities mentioned in published content. Any such holdings will be disclosed at the time of publication. Market data is provided on an "as-is" basis and may be delayed. Cashu Technologies Pty Ltd does not guarantee the accuracy, completeness, or timeliness of any information presented.

Cashu Markets
Cashu
Markets

Setting up your session...